Study of BMPR2-Activin Signaling in Group II Pulmonary Hypertension in Heart Failure Patients

What this Trial Is About

Researchers are investigating the BMPR2-activin signaling pathway in patients with pulmonary hypertension due to left heart disease PH-LHD, particularly focusing on its role in vascular health and disease progression. This observational study aims to understand how this pathway contributes to the development and possible reversal of PH-LHD, using advanced molecular biology techniques, cardiac imaging, and tissue analysis. The study includes heart failure patients of various causes and hopes to enhance precision medicine approaches and treatment strategies for PH-LHD. The study will enroll 150 heart failure patients who will undergo invasive hemodynamic assessment through right heart catheterization. Among these, about 70 are expected to have PH-LHD, while 80 will not. A subgroup of 40 patients listed for heart transplantation will participate in a detailed substudy involving thoracic CT scans and histological examination of explanted hearts. Researchers will analyze clinical data, biomarkers, molecular profiles, and imaging to assess vascular remodeling before and one year after transplantation. Participants will be followed for one year, during which clinical evaluations, biomarker collection, molecular studies, and hemodynamic and echocardiographic measurements will be performed. The primary outcomes include pulmonary vascular resistance and BMPR2-activin expression after 12 months. The study prioritizes inclusion of underrepresented groups, especially women, and aims to refine PH-LHD classifications and treatment criteria based on its findings.

Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.